Next Article in Journal
Bioformulations with Beneficial Microbial Consortia, a Bioactive Compound and Plant Biopolymers Modulate Sweet Basil Productivity, Photosynthetic Activity and Metabolites
Next Article in Special Issue
Presence of SARS-CoV-2 in a Cornea Transplant
Previous Article in Journal
Sarcoptes Infestation. What Is Already Known, and What Is New about Scabies at the Beginning of the Third Decade of the 21st Century?
Previous Article in Special Issue
Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
Communication

Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants

by 1,†, 2,†, 1 and 1,3,*
1
Department of Laboratory Medicine and Biotechnology, Tzu Chi University, Hualien 97004, Taiwan
2
Department of Biochemistry, Tzu Chi University, Hualien 97004, Taiwan
3
Department of Laboratory Medicine, Buddhist Tzu Chi General Hospital, Hualien 97004, Taiwan
*
Author to whom correspondence should be addressed.
The first two authors contributed equally to this work.
Academic Editor: Sonia Zuñiga
Pathogens 2021, 10(7), 869; https://doi.org/10.3390/pathogens10070869
Received: 24 May 2021 / Revised: 7 July 2021 / Accepted: 7 July 2021 / Published: 9 July 2021
(This article belongs to the Collection SARS-CoV Infections)
The COVID-19 pandemic was caused by SARS-CoV-2 infection. To prevent the spread of SARS-CoV-2, an effective vaccine is required. Two linear peptides from potential B-cell epitopes in the spike protein of SARS-CoV-2 (a.a. 440–460; a.a. 494–506) were synthesized and used to immunize rabbits. High-titer antibodies of IgG were produced, purified, and verified by Western blot analysis. Antibodies against these two epitopes could effectively neutralize SARS-CoV-2 pseudoviral particles with the spike proteins from not only the original strain (basal; wild-type), but also a strain with a single point mutation (D614G), and two other emerging variants (the Alpha and Beta variants) prevalent around the world, but not from SARS-CoV. In conclusion, antibodies against these two epitopes are protective. This information is important for the development of vaccines against SARS-CoV-2. View Full-Text
Keywords: COVID-19; SARS-CoV-2; spike protein; epitope; D614G; Alpha variant; Beta variant; neutralization; pseudovirus COVID-19; SARS-CoV-2; spike protein; epitope; D614G; Alpha variant; Beta variant; neutralization; pseudovirus
Show Figures

Figure 1

MDPI and ACS Style

Yang, C.-H.; Li, H.-C.; Lee, W.-H.; Lo, S.-Y. Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants. Pathogens 2021, 10, 869. https://doi.org/10.3390/pathogens10070869

AMA Style

Yang C-H, Li H-C, Lee W-H, Lo S-Y. Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants. Pathogens. 2021; 10(7):869. https://doi.org/10.3390/pathogens10070869

Chicago/Turabian Style

Yang, Chee-Hing, Hui-Chun Li, Wen-Han Lee, and Shih-Yen Lo. 2021. "Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants" Pathogens 10, no. 7: 869. https://doi.org/10.3390/pathogens10070869

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop